Released: 12/03/2020 Expires: 12/31/2021 (subject to change)
CE for this activity will not be available after this date.
Overview Diabetic retinopathy (DR) is a microvascular complication of diabetes that occurs when high blood glucose levels damage the retinal blood vessels. Ophthalmic vascular changes in patients with diabetes can lead to substantial morbidity due to retinal damage, vision loss, and/or blindness. An expert NP faculty guides the learner through the criteria to identify patients at risk for DR, screening tools that are available in primary care, and strategies to partner with patients to reduce barriers to attending screening and treatment appointments with their eye specialist. Objectives
Identify patients who are candidates for DR screening according to guideline recommendations.
Summarize recent clinical evidence on the safety and efficacy of anti-VEGF therapies for DR.
Incorporate strategies for effective patient-centered approaches to DR management, including education, promotion of adherence, and coordination of interdisciplinary care.
Explain individualized and evidence-based strategies to overcome barriers to treatment adherence.
Speakers Deborah Hinnen, APN, BC-ADM, CDCES, FAAN, FADCES Disclosure This program was planned in accordance with AANP CE Standards and Policies.
Debbie Hinnen - Lilly, Novo Nordisk, Sanofi, Janssen
All Planners have no relevant financial relationships to disclose. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the Pretest associated to the activity.
Complete the educational content:
Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
After completing all content, click on the blue Next Steps button:
Complete the post-test and pass with a score of at least 70% (4 attempts allowed).
Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE opportunity contact the AANP CE Center Manager at CECenter@aanp.org.
1.25 Contact Hour(s) of CE, 0.5 of which may be applied towards Pharmacology